Plenary programme

Will AI cure Atherosclerotic Cardiovascular disease
Thomas Lüscher, Zürich, Switzerland

Big data and artificial intelligence to redefine disease definition and advance drug development
Folkert Asselbergs, Amsterdam, The Netherlands

Atherosclerosis phenotyping using artificial intelligence: implications for imaging
Ron Blankstein, Boston, USA

Gain unprecedented insights into CVD with the latest -omics technologies using generative AI
Manuel Mayr, London, UK

Environmental pollution: a modifiable risk factor?
Thomas Münzel, Mainz, Germany

Immunometabolism as driving force of atherosclerosis
Train Chavakis, Dresden, Germany

Per particle importance of remnants vs. Lp(a) vs. LDL on cardiovascular disease risk
Elias Björnsson, Gothenburg, Sweden

Attacking Scylla or Charybdis: Cholesterol or weight reduction for reduction of atherosclerotic CVD?
Naveed Sattar, Glasgow, UK

Gender medicine: Effects of sex and gender on cardiovascular disease manifestation and outcomes
Vera Regitz-Zagrosek, Berlin, Germany

Deciphering the code: Exploring the influence of biological sex and cardiometabolic disease development
Karen Reue, Los Angeles, USA

Acute Coronary Syndromes in the absence of standard modifiable risk factors (SMURFs) and the impact of sex
Gemma Figtree, Sydney, Australia

Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women
Lale Tokgözoğlu, Ankara, Turkey